Milestone Pharmaceuticals Inc
MIST1.840USD
-0.010-0.54%
Cierre 11/04, 16:00（ET）Cotizaciones retrasadas 15 min
98.43MCap. mercado
PérdidaP/E TTM
Más Datos de Milestone Pharmaceuticals Inc Compañía
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Información de Milestone Pharmaceuticals Inc
Símbolo de cotizaciónMIST
Nombre de la empresaMilestone Pharmaceuticals Inc
Fecha de salida a bolsaMay 09, 2019
Director ejecutivoMr. Joseph Oliveto
Número de empleados33
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 09
Dirección420-1111 boul. Dr.-Frederik-Philips
CiudadMONTREAL
Bolsa de valoresNASDAQ Global Select Consolidated
PaísCanada
Código postalH4M 2X6
Teléfono15143360444
Sitio Webhttps://www.milestonepharma.com
Símbolo de cotizaciónMIST
Fecha de salida a bolsaMay 09, 2019
Director ejecutivoMr. Joseph Oliveto
Ejecutivos de Milestone Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 30 de oct
Actualizado: jue., 30 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Trails Edge Capital Partners LP
6.27%
Simplify Asset Management Inc
3.33%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
2.11%
Otro
82.38%
Accionistas
Accionistas
Proporción
Trails Edge Capital Partners LP
6.27%
Simplify Asset Management Inc
3.33%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
2.11%
Otro
82.38%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
12.62%
Individual Investor
3.61%
Investment Advisor/Hedge Fund
3.03%
Hedge Fund
2.58%
Venture Capital
2.30%
Research Firm
2.16%
Bank and Trust
0.02%
Otro
73.68%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
99
19.30M
22.71%
-5.65M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Trails Edge Capital Partners LP
5.33M
6.27%
+5.33M
--
Jul 14, 2025
Simplify Asset Management Inc
990.00K
1.16%
+140.00K
+16.47%
Jun 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
RTW Investments L.P.
2.51M
2.95%
--
--
Jun 30, 2025
Propel Bio Management, LLC
1.79M
2.11%
+340.00K
+23.42%
Jun 30, 2025
Alta Fundamental Advisers LLC
1.40M
1.65%
-28.50K
-2.00%
Jun 30, 2025
BML Capital Management LLC
1.14M
1.34%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
817.82K
0.96%
-148.10K
-15.33%
Jun 30, 2025
TD Securities, Inc.
750.00K
0.88%
--
--
Jun 30, 2025
Lion Point Capital, L.P.
548.81K
0.65%
--
--
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Simplify Propel Opportunities ETF
8.56%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
Proporción8.56%
SPDR S&P International Small Cap ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
